Literature DB >> 16821005

Multiple gene polymorphisms and warfarin sensitivity.

Eriko Shikata, Ichiro Ieiri, Shingo Ishiguro, Hiroshi Takane, Shigetsugu Ohgi, Kenji Otsubo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16821005     DOI： 10.1007/s00228-006-0173-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.

Authors:  Taisei Mushiroda; Yozo Ohnishi; Susumu Saito; Atsushi Takahashi; Yuka Kikuchi; Shigeru Saito; Hideki Shimomura; Yasuhiko Wanibuchi; Takao Suzuki; Naoyuki Kamatani; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2006-01-24       Impact factor: 3.172

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

4.  Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection.

Authors:  H Takahashi; T Kashima; S Kimura; N Muramoto; H Nakahata; S Kubo; Y Shimoyama; M Kajiwara; H Echizen
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-11-07

5.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

6.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Authors:  Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

7.  Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration.

Authors:  Norimoto Gotoh; Sachiko Kuroiwa; Takanobu Kikuchi; Jun Arai; Satoko Arai; Noriko Yoshida; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2004-10       Impact factor: 5.258

8.  Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

Authors:  Eriko Shikata; Ichiro Ieiri; Shingo Ishiguro; Hironao Aono; Kazuko Inoue; Tomoko Koide; Shigetsugu Ohgi; Kenji Otsubo
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

9.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

10.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962
View more
  1 in total

1.  Hypermethylation of brain natriuretic peptide gene is associated with the risk of rheumatic heart disease.

Authors:  Ni Li; Dawei Zheng; Lebo Sun; Huoshun Shi; Xiuying Zhu; Guodong Xu; Qinning Wang; Caimin Zhu; Guofeng Shao
Journal:  Biosci Rep       Date:  2017-01-17       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.